Stigma and bias involve negative attitudes, stereotypes, and discriminatory behaviors that devalue and dehumanize people living with cognitive decline, treating them as “other” or incapable. Stigma and bias around Alzheimer’s disease operate at individual, family, provider, and system levels and can result in delayed diagnosis, reduced use of services, and deepened racial, ethnic, and cultural inequities in care. Reducing these barriers requires culturally tailored education, anti‑stigma initiatives, provider training, legal and policy protections, and structural reforms to ensure equitable, trusted access to dementia diagnosis and support.

How stigma and bias limit help-seeking and access to services

• Stigma induces shame, fear, and concealment, leading people to avoid or delay diagnosis, treatment, and research participation. Fear of labels such as “senile” and the loss of independence causes people to avoid medical help and delaying early intervention such as anti-amyloid therapies when they are most effective.
• Reluctance to disclose symptoms, internalized negative beliefs, and anticipatory avoidance of social situations can increase isolation and restrict access to adequate care and post-diagnostic services.
• Dementia is often seen as a “normal” part of aging or something shameful, so families hide symptoms and postpone care, producing late diagnoses and poor service use.
• Physicians and other providers may feel ill-equipped to provide care for AD and be unsure about the efficacy of treatment, undermining screening, diagnosis, communication, and support.
• Racial and ethnic minoritized groups are less likely to receive timely diagnosis, dementia medications, or hospice, and more likely to experience poorer outcomes and aggressive end‑of‑life care. For example, Black Americans are 35% less likely to be diagnosed with AD and related dementias when compared to white Americans, despite national statistics that Blacks are 1.5 to 2 times as likely as whites to develop AD.

The Intersection of  biomedical innovation with stigma and bias in AD

• Fear of employment and insurance discrimination based on diagnosis, brain scans, or genetic tests deter seeking evaluation and research participation.
• New biomarker‑based early diagnosis may increase concerns about discrimination, particularly among Black adults, potentially worsening disparities if not paired with protections and anti‑stigma efforts.

Strategies to Reduce Stigma & Bias:

Targeted training and experiential learning effectively reduce stigma and bias among healthcare professionals treating AD by enhancing knowledge, empathy, and confidence. Examples of approaches include:

• Educational interventions incorporated into workshops, online modules, and academic detailing can improve knowledge and challenge negative stereotypes. The impact of these interventions can be measured using tools such as the Dementia Negative Stereotype Scale (DNS) and Alzheimer’s Disease Knowledge Scale (ADKS).
• Collaborative and structural changes that foster interprofessional teams with nurses, social workers, and others as well as culturally-sensitive training for diverse communities improve equitable care delivery.
• Experiential approaches that incorporate interdisciplinary methods and frameworks like DICE (Describe, Investigate, Create, Evaluate) with direct patient contact build empathy and promote person-centered care that emphasizes autonomy and identity combined with proactive education on risk reduction.

Public policy that helps reduced disparities arising from stigma and bias is critical to ensure health equity for all impacted by AD. The NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act extends the National Alzheimer's Project Act (NAPA) (P.L. 111-375) emphasizing the importance of investing in health aging and risk reduction and encourages diversity in clinical trials and care initiatives. The BOLD Act and recent BOLD Reauthorization Act supports public health infrastructure by funding state, local and tribal public health departments interventions focused on public health, increases data collection, analysis, and reporting on AD issues. It also establishes BOLD Public Health Centers of Excellence that work to increase adoption of evidence-based best practices.  State policies that promote public education to improve awareness of AD and brain health, the value early detection and diagnosis as well as providing financial and educational resources to support people living with AD, care partners, providers, and communities.

Implications:

Reducing stigma and bias starts with challenging simplified and often held stereotypes that people with AD lack agency and are fully dependent for care in activities of daily living. Instead, depictions of AD should be focused on it as a biomedical disease that varies from person to person, and like other biomedical diseases, can be prevented, treated, and managed. Effective strategies target multiple levels, from individual to policy, using education, contact, and cultural tailoring. These approaches help improve attitudes, access to care, and quality of life by challenging myths and fostering empathy. Additionally, peer support, intergenerational programs, life story vignettes, theater, music and art can humanize AD and build support networks.

Learn More

Alzheimer's Association. Overcoming Stigma

Mayo Clinic. Addressing Alzheimer's stigmas

Flipping Dementia Stigma

BOLD Public Health Center of Excellence on Dementia Caregiving (PHCOE-DC)

Dementia Friendly America. DFA Community Toolkit

Strengthening Responses to Dementia (STRiDE). Reducing Stigma

Voices of Alzheimer's. Bill of Rights for People Living with Alzheimer's Disease